Patient’s characteristics
| . | Gene therapy (n = 14) . | Haploidentical HSCT (n = 13) . |
|---|---|---|
| Median age in months (range) | 8 (1-11) | 7 (1-15) |
| Active infections at treatment | 9 | 5 |
| Maternal T cells (/µL): median (range) | 0 (0-8051) | 0 (0-270) |
| CD34+ cell dose (×106/kg): median (range) | 8.9 (1-22) | 7 (2.4-17) |
| Adverse events | ||
| Graft failure | 1 | 3 |
| GVHD | — | 4 |
| Dysimmunity | — | 3 |
| T-ALL | 4 | — |
| Time course of BCG infection in months: median (range) | 11 (8.9-14.6) | 25.5 (24.1-28.7) |
| Infection-related hospitalization duration: day per patient per year | 0.03 | 0.4 |
| Death | 2 | 2 |
| Median duration of follow-up in years (range) | 12 (1-15) | 6 (1-12) |
| . | Gene therapy (n = 14) . | Haploidentical HSCT (n = 13) . |
|---|---|---|
| Median age in months (range) | 8 (1-11) | 7 (1-15) |
| Active infections at treatment | 9 | 5 |
| Maternal T cells (/µL): median (range) | 0 (0-8051) | 0 (0-270) |
| CD34+ cell dose (×106/kg): median (range) | 8.9 (1-22) | 7 (2.4-17) |
| Adverse events | ||
| Graft failure | 1 | 3 |
| GVHD | — | 4 |
| Dysimmunity | — | 3 |
| T-ALL | 4 | — |
| Time course of BCG infection in months: median (range) | 11 (8.9-14.6) | 25.5 (24.1-28.7) |
| Infection-related hospitalization duration: day per patient per year | 0.03 | 0.4 |
| Death | 2 | 2 |
| Median duration of follow-up in years (range) | 12 (1-15) | 6 (1-12) |